Mechanisms of Comorbidities Associated With the Metabolic Syndrome: Insights from the JCR:LA-cp Corpulent Rat Strain by Diane, Abdoulaye et al.
Touro Scholar 
NYMC Faculty Publications Faculty 
10-2016 
Mechanisms of Comorbidities Associated With the Metabolic 
Syndrome: Insights from the JCR:LA-cp Corpulent Rat Strain 
Abdoulaye Diane 
W David Pierce 
Sandra Kelly 
Sharon Sokolik 
Rebecca Hutcheson 
New York Medical College 
See next page for additional authors 
Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs 
 Part of the Pharmacology, Toxicology and Environmental Health Commons 
Recommended Citation 
Diane, A., Pierce, W. D., Kelly, S. E., Sokolik, S., Borthwick, F., Jacome-Sosa, M., et al. (2016). Mechanisms 
of domorbidities associated with the metabolic syndrome: Insights from the JCR:LA-cp corpulent rat 
strain. Frontiers in Nutrition, 3, 44. doi:10.3389/fnut.2016.00044 
This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for 
inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information, 
please contact daloia@nymc.edu. 
Authors 
Abdoulaye Diane, W David Pierce, Sandra Kelly, Sharon Sokolik, Rebecca Hutcheson, Petra Rocic, and 
Spencer Proctor 
This article is available at Touro Scholar: https://touroscholar.touro.edu/nymc_fac_pubs/18 
October 2016 | Volume 3 | Article 441
Review
published: 10 October 2016
doi: 10.3389/fnut.2016.00044
Frontiers in Nutrition | www.frontiersin.org
Edited by: 
Patrick Christian Even, 
Agro ParisTech, France
Reviewed by: 
Philippe G. Frank, 
François Rabelais University, France 
Lori Asarian, 
University of Zurich, Switzerland
*Correspondence:
Spencer D. Proctor 
spencer.proctor@ualberta.ca
Specialty section: 
This article was submitted 
to Clinical Nutrition, 
a section of the journal 
Frontiers in Nutrition
Received: 07 June 2016
Accepted: 23 September 2016
Published: 10 October 2016
Citation: 
Diane A, Pierce WD, Kelly SE, 
Sokolik S, Borthwick F, Jacome-
Sosa M, Mangat R, Pradillo JM, 
Allan SM, Ruth MR, Field CJ, 
Hutcheson R, Rocic P, Russell JC, 
Vine DF and Proctor SD (2016) 
Mechanisms of Comorbidities 
Associated With the Metabolic 
Syndrome: Insights from the 
JCR:LA-cp Corpulent Rat Strain. 
Front. Nutr. 3:44. 
doi: 10.3389/fnut.2016.00044
Mechanisms of Comorbidities 
Associated with the Metabolic 
Syndrome: insights from the  
JCR:LA-cp Corpulent Rat Strain
Abdoulaye Diane1, W. David Pierce2, Sandra E. Kelly1, Sharon Sokolik1, Faye Borthwick1, 
Miriam Jacome-Sosa1, Rabban Mangat1, Jesus Miguel Pradillo3, Stuart McRae Allan4, 
Megan R. Ruth5, Catherine J. Field5, Rebecca Hutcheson6, Petra Rocic6, 
James C. Russell1, Donna F. Vine1 and Spencer D. Proctor1*
1 Metabolic and Cardiovascular Diseases Laboratory, Division of Human Nutrition, Alberta Diabetes and Mazakowski Heart 
Institutes, University of Alberta, Edmonton, AB, Canada, 2Department of Sociology, University of Alberta, Edmonton, AB, 
Canada, 3Universidad Complutense de Madrid, Madrid, Spain, 4Faculty of Biology, Medicine and Health, University of 
Manchester, Manchester, UK, 5Department of Agricultural Food and Nutritional Science, University of Alberta, Edmonton, 
AB, Canada, 6New York Medical College, New York, NY, USA
Obesity and its metabolic complications have emerged as the epidemic of the new 
millennia. The use of obese rodent models continues to be a productive component 
of efforts to understand the concomitant metabolic complications of this disease. In 
1978, the JCR:LA-cp rat model was developed with an autosomal recessive corpulent 
(cp) trait resulting from a premature stop codon in the extracellular domain of the leptin 
receptor. Rats that are heterozygous for the cp trait are lean-prone, while those that are 
homozygous (cp/cp) spontaneously display the pathophysiology of obesity as well as a 
metabolic syndrome (MetS)-like phenotype. Over the years, there have been formidable 
scientific contributions that have originated from this rat model, much of which has been 
reviewed extensively up to 2008. The premise of these earlier studies focused on char-
acterizing the pathophysiology of MetS-like phenotype that was spontaneously apparent 
in this model. The purpose of this review is to highlight areas of recent advancement 
made possible by this model including; emerging appreciation of the “thrifty gene” 
hypothesis in the context of obesity, the concept of how chronic inflammation may drive 
obesogenesis, the impact of acute forms of inflammation to the brain and periphery 
during chronic obesity, the role of dysfunctional insulin metabolism on lipid metabolism 
and vascular damage, and the mechanistic basis for altered vascular function as well as 
novel parallels between the human condition and the female JCR:LA-cp rat as a model 
for polycystic ovary disease (PCOS).
Keywords: obesity, thrifty genotype, metabolic syndrome, immune function, inflammation, cardiovascular 
diseases, pcos, JCR rat
iNTRODUCTiON
Obesity and the Clinical Problem for Our Generation
Obesity and its metabolic complications have emerged as the epidemic of the new millennia. 
Fueled by a caloric-dense (and nutrient-poor) food chain that is readily available in most developed 
countries, the current generation reflects the expression of a human phenotype plagued by the 
“obesogenic” environment. We have become so efficient at creating foods that target brain reward 
FiGURe 1 | The JCR:LA-cp rat: useful animal model for studies of metabolic syndrome and mechanisms of associated comorbidities.
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pathways to stimulate addictiveness and palatability, that we now 
suffer from the health consequences of not being able to alter our 
behavior away from this food environment. So too, we are just as 
guiltily of bestowing this new found talent on the next generation 
of young adults.
For many scientists, this problem has become a life-long com-
mitment to understand how overnutrition and nutrient-poor 
choices on the backdrop of the existing food chain could result in 
such a devastating change to our metabolic prognosis in such a 
short period of time. Animal models have been a prominent tool 
in this endeavor. One such model, the JCR:LA-cp rat (re-derived 
in Edmonton, AB, Canada in 1978 by Dr. James C. Russell), has 
received significant attention. For the last three decades, this 
model has appeared in the literature every year, often in numer-
ous forms spanning facets of nutrition, endocrinology, metabolic 
syndrome (MetS), obesity, lipid metabolism, vascular myocardial 
pathophysiology, and pharmacology (Figure 1).
The JCR:LA-cp Rat
In 1978, at the fifth backcross to the LA/N strain [including 
elements of the corpulent (cp) trait], initial breeding stock was 
sent from National Institutes of Health (NIH) by Dr. Carl T. 
Hanson to the laboratory of one of the authors (James C. Russell) 
at the University of Alberta. These rats were the founders of a 
colony that retained ~3% of the genome derived from the obese 
spontaneously hypertensive rat (or SHROB). Unlike other NIH 
colonies, at the time, that were maintained inbred and congenic, 
the JCR:LA-cp strain has been maintained as a closed outbred 
colony at the University of Alberta to retain the unknown genetic 
elements leading to early development of cardiovascular disease 
(CVD).
The formidable contributions that have originated from this 
rat model have been well documented and reviewed extensively 
up to 2008 (1–3). The premise of the early studies focused on 
characterizing the pathophysiology of MetS-like phenotype that 
was spontaneously apparent in this model. Highlights of the work 
from this period included useful descriptions of the biochemi-
cal profile, careful reports of glucose and insulin metabolism, 
endothelial function and its impairment, and unique observa-
tions of early vascular atherogenesis.
Contributions of the JCR:LA-cp Rat and 
Recent Advancements
The purpose of this review is to celebrate the major contributions 
that this rat model has served over many years and to highlight 
recent advancements. In a unique way, this model has been 
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carefully studied, yet successfully pervasive into the broad areas 
of research that underpin our understanding of obesity and the 
MetS.
We wish to highlight areas of advancement made possible 
by this model including; emerging appreciation of the “thrifty 
gene” hypothesis in the context of obesity, the concept of how 
chronic inflammation may drive obesogenesis, the impact of 
acute forms of inflammation to the brain and periphery during 
chronic obesity, the role of dysfunctional insulin metabolism on 
lipid metabolism and vascular damage, the mechanistic basis for 
altered vascular function as well as novel parallels between the 
human condition and the female JCR:LA-cp rat as a model for 
polycystic ovary disease (PCOS).
OBeSiTY: TeSTiNG THe “THRiFTY GeNe” 
HYPOTHeSiS OF ADAPTATiON TO 
DieTARY eNeRGY iNTAKe
The prevalence of obesity is continuing to increase at an alarming 
rate in both economically advanced Western societies and devel-
oping countries in economic–nutrition transition (4). Obesity 
is linked to adverse short-term and long-term health outcomes, 
including increased risk of CVD and insulin resistance leading to 
overt type 2 diabetes (T2D) (5, 6). Genetic differences between 
individuals explain a major proportion of the within-population 
variation in body mass index (7). However, genetic susceptibility 
alone may not result in obesity without other environmental 
influences (8). A positive energy balance beyond meeting energy 
requirements results in excess dietary energy intake being prefer-
entially stored as triglycerides (TG) in adipose tissue, resulting in 
an increase in body weight and fat mass. Obesity can be viewed 
as a result of physiological dysfunction or perturbation in normal 
feedback mechanisms relating to feeding behavior and energy 
balance. The adaptive response or “thrifty gene” theory of obesity 
explains how genes favoring the efficient use of energy store in 
periods of feast followed by famine result in obesity in the food-
rich or “obesogenic” environment of prosperous societies (9, 10). 
This “thrifty gene” hypothesis has been the dominant theory of 
the developmental origins of obesity and related chronic disease. 
The “thrifty gene” hypothesis provides a potential explanation 
for the dramatic rate of T2D and obesity prevalence in Pima 
Indian population of Arizona relative to the genetically similar 
Pima Indians in Mexico (11). However, there are only limited 
experimental studies that have tested the adaptive-survival value 
of an obese-prone genotype. Our ongoing research is based on 
the JCR:LA-cp rodent model that expresses the corpulent (cp) 
autosomal recessive trait (cp), a nonsense Tyr763Stop mutation 
in the Ob-R gene, resulting in a total absence of functional 
leptin receptors (12). Animals that are homozygous for the cp 
trait (cp/cp) are obese-prone, hyperphagic, and develop features 
of the MetS, similar to the metabolic aberrations observed in 
the clinical setting (13). Animals that are heterozygous for the 
cp trait (+/cp) or wild type (+/+) are lean-prone, have normal 
food intake, and do not develop the MetS. To verify the adap-
tive response hypothesis that an obese-prone genotype confers 
a survival advantage when challenged with dietary energy 
restriction and food-seeking behavior induced activity, juvenile 
(35–40 days) male JCR:LA-cp rats (obese-prone and lean-prone) 
were exposed to 1.5 h/day of feeding and 22.5 h/day of voluntary 
wheel running (14). We have shown that this experimental design 
leads to increased wheel running or food-seeking behavior and 
self-starvation (14). Initial body weights were similar in both 
groups of animals; however, the obese-prone animals survived 
twice as long (8.2 ± 1.1 vs. 3.5 ± 0.2 days) and ran similarly, com-
pared to their lean-prone counterparts (14). A follow-up study 
showed that prior conditioning with dietary energy restriction 
for 1  week provided a survival advantage to the obese-prone 
JCR:LA-cp phenotype (15). Dietary energy restriction primed 
the animals to regulate energy homeostasis pathways following 
exposure to continued energy restriction and food-seeking-
related activity (15). The obese- and lean-prone phenotypes have 
metabolic differences, which we have shown are associated with 
alterations in feeding-related neuropeptide gene expression in the 
arcuate nucleus of the hypothalamus including NPY, Orexin A, 
CART, and POMC. In addition, hypothalmic pro-inflammatory 
cytokines and oxidative stress markers IL-6, Tnf-α, and NF-kβ, 
superoxide dismutase-1 (SOD1), glutathione reductase (GRx), 
glutathione peroxidase (GPx), and catalase mRNA are elevated 
in the obese-prone phenotype (16). Interestingly, when the 
obese- and lean-prone animals are exposed to the same degree 
of dietary energy restriction, these hypothalamic inflammatory 
and oxidative stress markers were improved in the obese-prone 
phenotype, while they are exacerbated in the lean-prone pheno-
type (16). These findings demonstrate that, in juvenile JCR:LA-cp 
rodents, the metabolic and neural adaptation to energy restriction 
are dependent on the phenotype, and this can confer a survival 
advantage (16). Overall, our research findings suggest that obesity 
is a developmental outcome dependent on the interrelationship 
of an obese-prone genotype and feeding conditions/“obesogenic” 
environment. The JCR:LA-cp rodent offers a unique opportunity 
to study the underlying mechanisms of the behavioral and physi-
ological pathways involved in the development of obesity and the 
possible conference of evolutionary survival traits.
CHARACTeRiZATiON OF THe ALTeReD 
iMMUNe FUNCTiON iN OBeSiTY USiNG 
THe JCR:LA-cp RAT MODeL: MODULATiON 
wiTH AGe AND DieTARY FAT
Obesity is often recognized as a chronic inflammatory state with 
altered immune responses, including T cell dysfunction (17–19). 
The JCR:LA-cp rat model of the MetS shares altered immune 
function, similar to that observed clinically in obese individuals 
(17–19). The obese-prone rodent model has chronic low-grade 
systemic inflammation (20–22) and, recently, has been shown 
to have inflammation in the brain (23, 24). Our group has also 
demonstrated significant alterations in the acquired immune 
system of the obese-prone phenotype (19, 25–27). The altered 
T cell function in the JCR:LA-cp rat appears to be dependent on 
the age of the animal and length of time of exposure to a high-fat 
diet. When a high-fat diet is introduced at 8 weeks of age and 
fed for 3 weeks, the obese-prone rats have fewer splenocytes (an 
indicator of the peripheral lymphopenia) compared to their lean-
prone counterparts (27). The obese-prone animals also have a 
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higher proportion of macrophages, T-cells (primarily CD8+ and 
CD4+) and CD4+CD25+ (T regulatory cells) (27). This inflam-
matory T cell response would contribute to the overall chronic 
inflammation observed in these animals. When splenocytes from 
the JCR:LA-cp rats are stimulated ex  vivo with Concanavalin 
A (ConA, polyclonal T cell mitogen), they produce the same 
amount of IL-2 (proliferative cytokine) but have increased levels 
of the inflammatory cytokine IL-6 (27). In mesenteric lymph 
nodes (MLN), which are part of the gut-associated lymphoid 
tissue and visceral adipose tissue, the obese-prone rats have a 
lower proportion of T-cells (both CD4+ and CD8+ cells) and 
fewer mature T cells (CD3+CD90+), with a higher proportion 
of CD4+CD25+ (T regulatory cells) (27). Despite lower T cell 
numbers, ex vivo, MLN from obese-prone rats produce higher 
amounts of IL-2, IL-10, IFN-γ, and Tnf-α after stimulation with 
Con A (27), suggestive of a highly reactive pro-inflammatory 
state in the intestine. When a high-fat diet was fed for 3 weeks 
to older JCR:LA-cp animals (aged 14  weeks), splenocytes had 
a lower inflammatory response in IL-6 and IL-10 production 
in the unstimulated condition. In stimulated conditions [with 
ConA, lipopolysaccharide (LPS), or pokeweed], a lower produc-
tion of IFN-γ and decreased IL-1β (LPS) and IL-10 (Con A) was 
observed (25). This suggests, similar to the human condition, that 
the animals have some degree of immunosuppression and which 
would make them susceptible to infection. In splenocytes, there 
was a greater number of CD4+ cells and fewer CD4+CD25+ 
cells, B cells, and macrophages in obese-prone animals. In MLN, 
a greater production of IL-4 following Con A stimulation, and 
IL-1β, IL-10, and IFN-γ after stimulation with LPS was observed 
(26), again suggestive of intestinal inflammation or increased 
exposure to antigens (perhaps microbiome) from the intestine. 
In addition, there was a higher proportion of CD3+CD8+ cells 
and a lower proportion of CD4+CD25+ in the obese-prone 
animals (26), consistent with chronic inflammation. When a 
high-fat diet is introduced at 3 weeks of age and fed for 13 weeks, 
the obese-prone rats have a lower proportion of CD3+ cells 
(both CD4+ and CD8+), a higher proportion of CD4+CD25+. 
In addition, these animals have naive or less mature CD4+ 
cells and activated B cells in the spleen compared to lean-prone 
control animals (20), which would leave the animals more prone 
to infection. With the exception of IL-2 production, which did 
not differ between obese- and lean-prone animals, the ex vivo 
production of cytokines after stimulation was exacerbated in this 
group compared to previous studies in older animals or fed for 
shorter periods of time. After Con A stimulation, splenocytes 
from obese-prone animals produced lower levels of IL-1β (43%), 
IL-4 (53%), Tnf-γ (31%), and IFN-γ (31%), and twofold greater 
IL-6 compared to lean-prone animals (20).
In summary, the obese-prone JCR:LA-cp rat displays an 
immune dysfunction that is similar to that reported in obese 
individuals (17–19, 28), which suggest lymphopenia and immu-
nosuppression and abnormal inflammatory responses to immune 
challenges. Differences in immune cell type and function are 
observed in both the intestinal lymphoid tissue and peripheral 
immune system suggesting that there is both systemic and intes-
tinal involvement. Interestingly, we have learned that the altered 
immune profile of the JCR:LA-cp rat is also modified by the age 
and length of feeding period of a high-fat diet. Additionally, we 
have also demonstrated that immune dysfunction in this model 
can be improved by dietary supplementation with long-chain 
polyunsaturated fatty acids (PUFA), including trans-vaccenic 
acid (20, 27) and fish oil containing docosahexanoic and eicosa-
pentanoic acid (25, 26).
iNFLAMMATiON, STROKe, AND 
iNFeCTiON iN OBeSiTY
We and others have contributed to the fact that high levels of cir-
culating biomarkers of inflammation are present in the obese state 
(29). We know that obese individuals are more likely to develop 
other chronic inflammatory conditions, including certain forms 
of cancer, diabetes, cardiovascular, and cerebrovascular disease. 
Mechanisms by which obesity alters immune and inflammatory 
responses and how these changes contribute to the development 
of other diseases are still not clear.
Stroke is a major cause of morbidity and mortality, and the 
incidence of an ischemic episode has been associated with periph-
eral and central immune dysfunction (30). Chronic systemic 
inflammatory conditions, such as infections, atherosclerosis, 
diabetes, and obesity are associated with increased risk of stroke, 
suggesting that these conditions and associated inflammation 
may contribute to the development of stroke (30). In this respect, 
aged JCR:LA-cp rats have been shown to have increased brain 
inflammation using PET imaging (23). Furthermore, patients 
with multiple risk factors for stroke, in the absence of any 
brain pathology, have also been shown to have increased brain 
inflammation, and this may be associated with increased risk for 
cerebral ischemia (23). Despite research efforts, there has been 
a lack of translation of these findings from bench to bed side in 
stroke patients. One reason for this may be the failure to consider 
clinical comorbidities in experimental models of stroke. IL-1 is 
altered peripherally in obesity and is also an important mediator 
of ischemic brain injury (31). IL-1 receptor antagonist (IL-1Ra) is 
protective against ischemic brain damage in healthy animals (31). 
After cerebral ischemia, aged JCR:LA-cp rats showed increased 
blood brain–barrier disruption and brain inflammation com-
pared to their lean-prone counterparts, and this was reduced fol-
lowing systemic administration of IL-1Ra. IL-1Ra treatment was 
also shown to significantly reduce the infarct volume (measured 
by MRI) in obese-prone animals, further supporting IL-1Ra as a 
lead candidate for the treatment of ischemic stroke (24).
Bacterial infections have been proposed to contribute to stroke 
development and may worsen ischemic event outcomes (32). 
In  this setting, a sustained pulmonary infection (Streptococcus 
pneumoniae isolate) induced in JCR:LA-cp was used to inves-
tigate the effect of infection on vascular and inflammatory 
responses prior to and after cerebral ischemia (33). The results 
showed that the pneumonia infection augmented atherosclerosis 
and exacerbated ischemic brain injury via IL-1 and platelet-
mediated systemic inflammation pathways (33). Targeting these 
mechanisms could be therapeutically useful to prevent infection-
induced thrombo-inflammatory responses that may predispose 
individuals to ischemic vascular events and adversely affect stroke 
outcomes.
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DeveLOPMeNT OF DYSLiPiDeMiA 
DURiNG OBeSiTY AND 
HYPeRiNSULiNeMiA: OveRPRODUCTiON 
OF LiPiDS BY THe iNTeSTiNe AND 
BiOACTive TRANS-FATTY ACiDS
intestinal Contribution to 
Hypercholesterolemia and 
Diabetic Dyslipidemia
One of the most significant advances that have occurred over 
the last 5 years with respect to intestinal lipid metabolism is the 
understanding of how the gut contributes to whole body cho-
lesterol homeostasis (34). In particular, we now appreciate how 
these intestinal-based mechanisms become dysfunctional under 
conditions of obesity and insulin resistance. Using the JCR:LA-cp 
rat model, we have shown that circulating hyperinsulinemia (as 
is the case during conditions of MetS or prediabetes) can lead to 
increased absorption of both lipid and sterol from intestine that 
can, in turn, exacerbate dyslipidemia and CVD risk. Specifically, 
we have demonstrated that insulin resistance results in a chronic 
overproduction and excessive secretion of intestinal-derived 
apoB48-containing chylomicron particles. This finding is consist-
ent with studies from the JCR:LA-cp rat (35), the hamster (36), 
and, more recently, humans (37).
Mechanisms responsible for the overproduction of intestinal-
derived lipoproteins have been reviewed elsewhere (38) but can 
include stimulation by excess free fatty acids, manipulation of 
both GLP-1 and GLP-2, increased circulating Tnf-alpha, increased 
stability of apoB48, and the downregulation of enterocytic insulin 
receptor (IR) substrate-1. Work from our own group utilizing the 
JCR:LA-cp rat has also confirmed that this is likely multifactorial 
resulting from; suppression of enterocytic Pparα (39), increased 
SREBP-1 (40), decreased ABCG5/G8 (39), and increased phos-
phorylation of JNK (41). New emerging data also suggest that 
increased enterocytic Tnfα may also contribute to increased apoB 
per se (42). In addition, Parnell and Reimer have elegantly shown 
that there is an increase in satiety hormone (proglucagon, PYY, 
and ghrelin) mRNA expression in the JCR:LA-cp rat gut that may 
potentially contribute to intestinal lipid overproduction (43).
Importantly, these observations provide valuable mechanistic 
explanation for why those with the MetS and diabetes typically 
have a unique lipoprotein phenotype. Left untreated, those with 
obesity and early insulin resistance develop atherogenic dys-
lipidemia that renders a significantly increased CVD risk profile. 
Other efforts from our laboratory have used the JCR:LA-cp rat 
to better understand potential nutritional means to curb these 
metabolic impairments.
impact of Dietary Long-Chain Fatty 
Acids, PUFA, and Ruminant Trans-Fatty 
Acids to Lipoprotein Metabolism in the 
JCR:LA-cp Rat
Pharmaceutical compounds that activate peroxisome prolifera-
tor-activated receptor (PPAR)-α and PPAR-γ (e.g., fibrates and 
thiazolidinedione, respectively) have been successful as potent 
lipid-lowering and insulin-sensitizing therapies for CVD and 
diabetes-related dyslipidemia (44, 45). Activation of PPAR-α 
can effectively reduce plasma hypertriglyceridemia possibly via 
modulating fatty acid oxidation and energy homeostasis path-
ways. Upregulation of PPAR-γ activity has also been shown to 
normalize insulin sensitivity, improve lipid metabolism, and the 
clearance of lipoproteins, as well as restore vascular contractility 
and endothelial function (46). We became interested in the fact 
that a number of natural PPAR-α ligands exist among which 
include long chain and PUFA (e.g., oleic acid, arachadonic acid, 
eicosapentaenoic acid, and docosahexaenoic acid) (47,  48). 
More specifically, conjugated linoleic acid (CLA) is another 
naturally occurring agonist of the PPAR-α pathway, which has 
been proposed to be a primary mechanism via which CLA elicits 
pleiotropic effects (49, 50). It has now been recognized that aside 
from being converted to c9,t11-CLA in vivo, its precursor vac-
cenic acid (VA) may also have independent bioactivity in regu-
lating lipid metabolism. However, few studies have attempted to 
explore the metabolic pathways that are potentially modulated 
by VA. Using the obese JCR:LA-cp rat, we have offered a number 
of contributions to better understand the potential role of VA 
in activating and thereby regulating lipid metabolism (51, 52). 
Most recently, our group has obtained data indicating that VA 
is a potent PPAR-α and PPAR-γ agonist and strongly binds to 
the ligand-binding domain of both receptors. In accordance, we 
found a substantial elevation in energy expenditure during both 
light and dark cycle in VA-supplemented obese JCR:LA-cp rats 
(40, 53). The observed change in energy metabolism may partially 
be accredited to enhanced citrate synthase activity (an indicator 
of fatty acid oxidation) in liver and adipose tissue of VA/CLA-fed 
obese rats. Our evidence implies an active involvement of these 
nuclear receptors in regulating lipid metabolism, which is shared 
by other bioactive fatty acids such as DHA and c9,t11-CLA. These 
findings have been important in understanding the role of rumi-
nant derived trans-fatty acids as a class, and how they differ from 
pro-inflammatory industrial produced trans-fatty acids through 
the partial hydrogenation of vegetable oils (54).
In addition to PUFA and ruminant trans-fatty acids, prebiotic 
fibres have also been proposed to promote weight loss and lower 
plasma lipids; yet, the mechanisms are not fully understood. 
By  using the JCR:LA-cp rat, Parnell and Reimer have demon-
strated that a 10% dietary blend of prebiotic fibres (inulin and 
oligofructose) can lower total cholesterol concentrations. The 
dietary blend is thought stimulate cholesterol excretion in the 
form of bile as well as reduce hepatic steatosis through a FAS 
independent mechanism (55).
ARTeRiOGeNeSiS iS MeDiATeD BY 
microRNA iN THe CARDiOvASCULATURe 
AND iS ASSOCiATeD wiTH iNTeSTiNAL 
LYMPHATiC LiPOPROTeiNS iN THe 
MeTABOLiC SYNDROMe
Coronary collateral growth (arteriogenesis) is an important 
adaptive process in transient, repetitive coronary artery occlu-
sion, and myocardial ischemia, which occurs in stable angina 
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pectoris. Well-developed collateral networks are associated with 
lower incidence and severity of myocardial infarction (56). 
In contrast to angiogenesis, which is characterized by new vessel 
(capillary tube) formation, arteriogenesis is defined by remod-
eling and enlargement of small arterioles (with very low blood 
flow) to connect with larger conducting arteries. This process 
critically depends on both normal endothelial (57, 58) and vas-
cular smooth muscle cell (VSMC) function (59). Arteriogenesis 
has shown to be severely impaired in animal models exhibiting 
endothelial dysfunction, including the Zucker obese pre-diabetic 
(ZOF) rat (60) and the MetS obese-prone JCR:LA-cp  rat (59, 61, 
62). Human patients with impaired endothelial function and the 
MetS also exhibit impaired arteriogenesis (63–65).
We have recently shown that microRNA (miR)-145 and miR-
21 are important regulators of arteriogenesis. miR-145 levels are 
reduced in the JCR:LA-cp obese-prone rat compared to the lean-
prone metabolically normal animal, and when miR-145 levels 
are upregulated in the obese-prone animal, the result is complete 
restoration of coronary collateral growth (59). This effect was 
mediated by conversion of the aberrant synthetic VSMC pheno-
type to the normal contractile VSMC phenotype in the obese-
prone model (59). miR-21 levels were markedly increased in the 
heart of obese-prone animals, shown to be positively correlated 
with VSMC proliferation (66) and decreased apoptosis of neutro-
phils (66). Conversely, downregulation of miR-21 to levels found 
in lean-prone animals resulted in significant collateral growth 
recovery in obese-prone animals, associated with a decrease 
in VSMC proliferation (66); concomitant with a restoration of 
apoptosis of neutrophils (67). miR-21 is well accepted as a major 
pro-survival and pro-proliferative miR. Moreover, elevated miR-
21 levels were shown to be positively correlated with: increased 
expression of pro-proliferative markers (G1/S and G2/M cyclins 
and cyclin-dependent kinases); low expression of “tumor sup-
pressors” (p21, p27, and pRb); high expression of anti-apoptotic 
Bcl-2/Bcl-2 dimers; low expression of pro-apoptotic Bcl-2/Bax 
dimers (caspases 9 and 3); and decreased cytochrome c release 
from the mitochondria. Collectively, this study established that 
miR-21 can regulate neutrophil apoptosis and is a required 
component for successful collateral enlargement.
A Role for the Lymphatic expression of 
microRNA in Lipid Metabolism?
Interestingly, miR-21 expression was also significantly increased 
in jejunal enterocytes isolated from obese-prone JCR:LA-cp rat. 
The concentration of miR-21 in these animals was also increased 
in intestinal lymph and in the high-density lipoprotein (HDL) 
fraction isolated from the lymph (66). miR-21 levels in enterocytes 
were examined because, in the obese-prone animal, the intestine 
has overproduction of lipids associated with increased secretion 
of chylomicrons (CM), and HDL is also found in the lymphat-
ics isolated from the intestine (68). This intestinal secretion of 
lipids contributes significantly to the lipid–lipoprotein content 
of the lymphatics (68). Our results further indicated that 95% of 
miRs in intestinal lymph was associated with the HDL fraction, 
rather than the CM fraction (68). HDL has also been identified 
as a major transporter of miRs in the circulation (69, 70). More 
recently, the lymphatic system was revealed to be critical for the 
metabolic turnover of HDL and the reverse cholesterol transport 
system (71). These results suggest that altered enterocyte lipid 
and lipoprotein metabolism and/or HDL-dependent lymphatic 
cholesterol transport may be inter-related to the elevated cardiac 
miR-21 levels observed in the obese-prone JCR:LA-cp model.
eARLY iNTiMAL ATHeROGeNeSiS, 
ARTeRiAL LiPiD ReTeNTiON, AND NOveL 
THeRAPeUTiCAL TARGeTS
impact of Remnant Dyslipidemia to 
Atherosclerotic vascular Disease during 
Obesity and insulin Resistance
One of the major complications of obesity and T2D is the 
dramatic increased risk for CVD [specifically, atherosclerotic 
vascular disease (ASVD)], the reasons for which are multifacto-
rial. We have been very interested in understanding the role that 
chronic metabolic disease has in exacerbating dyslipidemia and 
how this mechanistically translates into greater lipid deposition 
within the arterial wall. Atherogenic cholesterol-dense lipopro-
teins (for example, low-density lipoprotein, LDL-C) are thought 
to permeate both intact and/or damaged arterial endothelium, 
become entrapped within the sub-endothelial space, and 
accumulate, resulting in inflammation and atheroma (72, 73). 
Although the literature documents a significant epidemiological 
and/or genetic (i.e., GWAS) association between raised circulat-
ing fasting LDL-C and ASVD risk, a large proportion of subjects 
diagnosed with CVD are either normolipidemic (normal levels 
of LDL) or have substantial residual risk (74–76). These data 
suggest that clinically, atheromata-associated cholesterol is 
derived from alternate sources, including non-fasting remnant 
lipid fractions as originally proposed by Zilversmit (77). Indeed, 
the International Atherosclerosis Society has recognized non-
fasting measurements of remnant cholesterol as a major target 
in their “Global Recommendations for the Management of 
Dyslipidemia” (78).
Interestingly, a series of recent publications authored by the 
Copenhagen Heart Study group have provided evidence for a 
major shift in the paradigm of atherogenesis (and potentially its 
therapy), suggesting that remnant (non-fasting) cholesterol is a 
major causative factor for ischemic heart disease (IHD) (79, 80).
Using the JCR:LA-cp rat, we have also collected a substantial 
array of preclinical data showing that remnant lipoproteins carry 
substantially more cholesterol (due to their size and enrich-
ment) compared to other atherogenic fractions. Using well-
established arterial perfusion methodology, we have conducted 
comparative dual labeling lipoprotein experiments. Cy5-labeled 
remnants were isolated, purified, and perfused simultaneously 
with Cy3-labeled LDL (designed to expose equivalent LDL-
derived apoB100 and remnant-derived apoB48). We observed 
a significantly greater number of LDL particles delivered to the 
vessel (4.5 ± 1 × 10−9 µg/µm2 tissue) as compared to remnants 
(0.48 ± 0.15 × 10−9 µg/µm2 tissue) (81). However, after extensive 
washout (a further 60  min) with lipoprotein-free buffer (i.e., 
representing residual retention), we observed significantly 
fewer (55% decrease) LDL particles remaining in the tissue 
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(2.9 ± 0.42 × 10−9 µg/µm2 “retention” vs. 4.5 ± 1 × 10−9 µg/µm2 
“delivery,” p < 0.05). Additional studies have gone on to show 
that there is an increased deposition of remnant lipoproteins in 
arteries from JCR:LA-cp rats as demonstrated by arterial perfu-
sion of equivalent numbers of particles. Mechanistically, we have 
proposed that this phenomenon may be due to (a) dyslipopro-
teinemia and/or (b) perturbations in the vessel wall. Crossover 
perfusion experiments have revealed that increased retention 
of the number of remnant lipoproteins during insulin resistance 
was due to differences in arterial vasculature and independent of 
other factors effecting particle dysfunction per se.
impact of Obesity and insulin Resistance 
on the extracellular Matrix and Arterial 
Remodeling
Our group has also shown that intestinal-derived remnant 
lipoproteins can colocalize with arterial biglycan in an insulin-
deficient model of type I diabetes ex vivo (82). Subsequently, we 
have demonstrated, in the JCR:LA-cp rat, that in the prediabetic 
milieu, aortic biglycan protein core content increases significantly 
with age and correlates linearly with increasing hyperinsuline-
mia. We know that the expression of biglycan protein core has 
been shown to be increased with fatty acids (83, 84), angiotensin 
II (85), and transforming growth factor-β (TGF-β) (86, 87). 
Consistent with this, obese JCR:LA-cp rats have been shown to 
have elevated concentrations of TGF-β (88) and non-esterified 
free fatty acids (51).
Arterial Retention of Remnant 
Lipoproteins and Associated Cholesterol 
Deposition in Response to ezetimibe and 
Simvastatin
Ezetimibe (EZ) is a pharmaceutical compound that selectively 
reduces intestinal cholesterol absorption by inhibiting the 
Niemann-pick C1-like 1 (NPC1L1) transporter (89) while 
Simvastatin (SV) is a HMG-CoA reductase inhibitor. Using the 
arterial perfusion approach in the JCR:LA-cp rat, we have shown 
that EZ treatment can ameliorate the deposition of arterial rem-
nants and associated cholesterol ex vivo (90). It is also intriguing, 
that the addition of SV to EZ appeared to have an additional 
benefit reducing arterial cholesterol deposition, suggesting a 
synergism of independent modes of action.
Combination of ezetimibe with 
Simvastatin improves Fasting and 
Postprandial Lipids
A study by Bozzetto et al. reported that the combination of EZ 
with SV in T2D subjects can beneficially impact both fasting and 
postprandial triglyceride-rich lipoproteins (91). They found that 
the addition of EZ to SV reduced the number of circulating CM 
particles (apoB48) in the postprandial state, while also lowering 
both fasting and postprandial chylomicron cholesterol (88). 
Postprandial data from studies in JCR:LA-cp rats are consistent 
with benefits of either EZ + SV therapy on both remnant particle 
metabolism and corresponding cholesterol (81).
Ischemic myocardial lesions constitute a critical end point 
in CVD. Previous studies using the JCR:LA-cp rat strain have 
demonstrated a correlation between the frequency of myocardial 
lesions with hyperinsulinemia (92). Hearts isolated from JCR:LA-
cp rats treated with either EZ (−84%) or EZ + SV (−84%) have 
displayed a significant reduction in the frequency of early stage 
2 myocardial lesions or very recent ischemic lesions undergoing 
scavenging and repair, characteristic for this strain at this age.
eSTABLiSHiNG JCR:LA-cp RODeNT RAT 
AS A MODeL OF SPONTANeOUS LeFT 
veNTRiCULAR HeART DYSFUNCTiON
The JCR:LA-cp rat has previously been identified as a model that 
also includes pathological complications of endothelial dysfunc-
tion and myocardial ischemia, in addition to other dysfunctional 
complications consistent with the MetS (41, 92, 93). We have 
recently demonstrated that JCR:LA-cp rats exhibit significant 
cardiac dysfunction and present as a useful animal model of 
spontaneous LV dysfunction (94). JCR:LA-cp rats were subjected 
to Doppler echocardiography analysis (Vevo 770 Micro-Imaging 
system). 2-D parasternal long- and short-axis images of the left 
ventricle (LV) were obtained using a 25-MHz linear-array trans-
ducer and doppler probe in anatomical M-mode at the level of 
papillary muscles at a sweep speed of 150 mm/s. We observed that 
JCR:LA-cp rats exhibited distinct signs of cardiac dysfunction, 
and that hearts exhibited a marked increase (~40%) in LV mass 
vs. their lean counterparts. Echocardiographical analysis also 
revealed that hearts from JCR:LA-cp rats had an increased early 
(MV-E) filling velocity (~40%) and reduced late (MV-A) filling 
(~15%) velocity compared to age-matched lean rats. We further 
revealed that JCR:LA-cp rats had a restrictive filling pattern, shown 
by a significantly shortened isovolume relaxation time (IVRT) 
(~30% decrease). Finally, we found that JCR:LA-cp rats exhibited 
progressive worsening of diastolic filling properties, with a 1.6-fold 
increase in the ratio of early to late filling velocity (E/A).
THe FeMALe JCR:LA-cp RAT AS A MODeL 
OF POLYCYSTiC OvARY SYNDROMe 
AND CARDiOMeTABOLiC RiSK
The JCR:LA-cp Rat as a Spontaneous 
Model of PCOS
Polycystic ovary syndrome (PCOS) has become an increasing 
public health concern given its association with menstrual 
dysfunction, infertility, MetS, T2D, and CVD risk (95, 96). The 
syndrome afflicts 5–18% of women in their reproductive years, in 
adolescents to premenopausal women. PCOS is diagnosed by the 
presence of clinical or biochemical hyperandrogenemia, men-
strual irregularity, and/or polycystic ovaries (97). The incidence 
of PCOS is twofold to threefold greater in overweight-obese ado-
lescents and women and is coassociated with features of the MetS 
including obesity, impaired insulin sensitivity, and dyslipidemia 
predisposing women to increased risk of prematurely developing 
T2D and CVD (96, 98, 99). Animal models of PCOS have been 
used to further understand the role of androgens, in particular 
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testosterone, on the development of the metabolic aberrations in 
this condition, and the features of these models have been previ-
ously reviewed (100, 101). These models have primarily used 
testosterone to induce PCOS; however, the JCR:LA-cp rodent 
model is the only model to spontaneously develop PCOS in con-
ditions of the MetS (102). The significance of the JCR:LA-cp rat 
in this context is the similarity to the human condition in which 
the development of the PCOS phenotype is preceded by increased 
adiposity and insulin resistance. Interestingly, we have known, for 
some time, that female homozygous JCR:LA-cp rats are infertile 
but have only recently begun to appreciate the metabolic impac-
tions. In humans, females that carry a predisposition for insulin 
resistance due to family history often see a clinical presentation 
that antagonizes endocrine–reproductive dysfunction, a feature 
that is also observed in female JCR:LA-cp rats (96, 103, 104).
Cardiometabolic Risk, Dyslipidemia, and 
the Hypothalamic–Pituitary–Gonadal Axis
The pathogenesis of PCOS is linked to altered hypothalamic–
pituitary–gonadal axis function and perturbed insulin and 
testosterone metabolism (105, 106). One of the major areas of 
research in the PCOS-prone JCR:LA-cp rodent model is under-
standing the distinct mechanisms of androgens and insulin in 
the cardiometabolic manifestations, particularly dyslipidemia 
and CVD risk (102, 107, 108). Dyslipidemia occurs in greater 
than 70% of PCOS patients and is positively correlated with 
increasing quartile of plasma hyperandrogenemia (97, 99). We 
have characterized the dyslipidemic profile of the PCOS-prone 
JCR:LA-cp rodent model, which has markedly elevated fasting 
and non-fasting plasma TG, total cholesterol (TC), apoB48, and 
apoB100 (markers of intestinal CM and hepatic very low-density 
lipoprotein and low-density lipoproteins, respectively) compared 
to control animals (35, 104). PCOS-prone animals have twofold 
the intestinal triglyceride, cholesterol, and apoB48 secretion in 
the fasted state compared to their lean-prone control counter-
parts, and this is associated with increased mRNA expression of 
SREBP-2, LDLR, and apoB (102, 107). When given dietary lipid, 
this elevated CM lipoprotein particle (apoB48) and lipid (cho-
lesterol and TG) secretion is further exacerbated (107). We have 
further shown, in this model, that plasma testosterone and insulin 
are positively correlated with fasting and non-fasting plasma TG 
and apoB48, consistent with the role of these lipogenic mediators 
in the development of dyslipidemia in PCOS, insulin resistance, 
and obesity (106, 107, 109).
Intervention with flutamide, an androgen receptor (AR) 
inhibitor, has confirmed that testosterone action via the AR medi-
ates apoB-hyperlipoproteinemia and hypertriglyceridemia, and 
this appears to be independent of effects on insulin (110). Fasting 
plasma apoB100, apoB48, and TG concentrations were lowered by 
25–50% in animals treated with flutamide. Flutamide–metformin 
combination treatment similarly lowered these parameters; 
however, metformin treatment alone had no effect on fasting 
plasma lipids, indicating a predominant effect of the AR inhibitor 
to mediate lowering of plasma lipids. Additionally, the intestinal 
secretion of TG, cholesterol, and the cholesterol/apoB48 and 
TG/apoB48 (a marker of lipid per CM particle secreted from the 
intestine) were markedly reduced following flutamide treatment. 
Hepatic and intestinal lipogenic gene expression showed that 
flutamide may lower hepatic SREBP-1, LDLR, and HMGCR in 
PCOS-prone animals (110). Interestingly, PCOS-prone animals 
have reduced IR, MAPK1, AKT2, and PTPN1 mRNA expres-
sion in the intestine, but not the liver. However, flutamide and 
metformin treatment appeared to favor hepatic upregulation of 
the IR mRNA, as well as MAPK1 and protein kinase B (AKT2); 
however, in the intestine, MAPK1 was downregulated, and no 
effect on AKT2 mRNA expression was observed in PCOS-prone 
animals. Overall, these findings indicate that lipogenic and insu-
lin signaling gene expression is altered in PCOS-prone animals 
compared to lean-prone controls. Effects of AR inhibition and 
insulin-sensitizing treatments appear to modify these pathways 
in association with improvements in plasma and intestinal secre-
tion of lipids (110).
energy Restriction and exercise 
intervention in the Female JCR:LA-cp Rat
In the PCOS-prone model, we have shown that energy restriction 
and voluntary exercise intervention (4 h/day) at an early life stage 
can significantly attenuate reproductive and cardiometabolic 
aberrations (111). The combination of diet and exercise was 
shown to lower total body weight gain and body fat mass by 
30% in PCOS-prone animals. Consistent with our ongoing 
studies on dietary energy restriction and food-seeking-induced 
exercise (112, 113), we have also found that energy restriction 
independently induces food-seeking behavior related activity in 
the PCOS-prone animal, favoring an increase in energy expendi-
ture. In terms of cardiometabolic risk, the combination of energy 
restriction and exercise decreased fasting plasma TG and apoB48 
in PCOS-prone animals. In addition, the combination of exercise 
and dietary energy restriction increased serum hormone-binding 
globulin and free androgen index, and normalized mRNA 
expression of hypothalamic CART and Kisspeptin. Collectively, 
these findings were associated with improvements in follicular 
morphology and estrus cyclicity. In similar exercise conditions, 
we have shown that the addition of metformin–flutamide treat-
ment lowers total body weight and body fat-pad weight and tends 
to lower fasting plasma lipids. Interestingly, a combination of 
both metformin and flutamide treatment, in addition to exercise 
further reduces free Testosterone and improves estrus cyclicity 
compared to exercise alone (113).
The findings of this work have revealed voluntary exercise has 
modest effects on cardiometabolic risk factors, and the inclusion 
of medications that specifically target insulin resistance and 
dyslipidemia are required to modulate these risk factors in this 
obese PCOS-prone model. These results have also highlighted 
the necessity for early intervention with combinations of lifestyle 
and/or dietary pharmaceutical medication to modulate the hypo-
thalamic–pituitary–ovary axis.
iMPACT OF JCR:LA-cp RAT MODeL TO 
TRANSLATiONAL OUTCOMeS FOR OBeSiTY
One measure of impact for the appropriateness of animal 
models to research is the usefulness of preclinical outcomes for 
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clinical translation. Perhaps the most successful application of 
the JCR:LA-cp rat model has been its suitability to study the 
progression of metabolic disease from initial stages of over-
nutrition (without the need for dedicated high caloric diets), 
resulting in the development of insulin resistance through to 
the phenotypic complications of hyperinsulinemia and hallmark 
conditions of the MetS. Many of the advances discussed in this 
review have made an impact to a better understanding of the 
human clinical condition. One such example is the revelation of 
how the intestine integrates and coordinates whole body lipid 
metabolism more prominently than previously appreciated 
(114). The discovery that the intestine will contribute to dyslipi-
demia through unregulated overproduction of lipids has been 
confirmed clinically in those with insulin resistance and T2D 
(115, 116). This in turn has provided a new platform for modes 
of action of different classes of pharmaceutical compounds; 
including intestinal cholesterol transporter inhibition and incre-
tion blockade. At the same time, the understanding of remnant 
cholesterol metabolism and how this relates to early conditions 
of childhood obesity has also come to the fore in the context of 
potential subclinical risk of CVD (117, 118).
The vision for this research sector will be to continue to strive 
for ways to aid the younger generation to become more aware 
of the comorbidities of obesity in childhood, and how they will 
progress into adulthood. In order to achieve this, we will have 
to target methodologies that identify metabolic risk of obesity 
in the younger generation that can have usefulness in the clinic 
and beyond.
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